#1 investment play for the biggest medical breakthrough since penicillin

If you act on the information I'm giving you today, you could walk away wealthier than you ever thought possible…

Dear Reader, We are living through the biggest medical revolution since Alexander Fleming discovered penicillin in 1928… This phenomenon is that big. A new "miracle drug" is on the market that has been shown to slash the risk of up to 10 different cancers… Reduce heart attack and stroke risk by 20%... Even help treat dementia, liver disease and depression… Which is why the FDA calls it "a major advance for public health." And the New York Times imagines "a future in which almost everyone is taking some variety of [this drug], and with a pretty good reason to do so." But… unlike with 99% of medical breakthroughs that have come before it… it's not just Big Pharma that's set to reap the biggest financial rewards. You see, the demand for this miracle drug has grown so big, so fast, that it's blindsided the industry. And there is now a huge supply shortage. It's a major problem. So, the FDA has stepped in… It's triggered a little-known loophole... buried in section 503B of the Drug Quality and Security Act… This loophole effectively brings these new miracle drugs "off patent" for a short amount of time… Creating a once-in-a-lifetime profit window for investors. In short: If you understand what's happening right now — and act on the information I'm giving you in this urgent presentation — you could walk away wealthier than you ever thought possible. But first, you should know — there is a catch… This loophole isn't going to be around for long. As you would expect, Big Pharma is doing everything it can to get it closed for good. We now have a brief profit window to capture the biggest gains before it slams shut. So, there isn't a minute to waste… Go here to watch my urgent presentation now. To good profits, Adam O’Dell Chief Investment Strategist, Money & Markets (c) 2024 Money & Markets, LLC. All Rights Reserved. Protected by copyright laws of the United States and treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of Money & Markets. 702 Cathedral Street, Baltimore, MD 21201. (TEL: 800-684-8471). Legal Notice. The mailbox associated with this email address is not monitored, so please do not reply. However, your feedback is very important to us so if you would like to contact us with a question or comment, please click here. Remove your email from this list: Click here to Unsubscribe.